CD103 – CD11b+ dendritic cells regulate the sensitivity of CD4 T-cell responses to bacterial flagellin

SM Atif1, S Uematsu2, S Akira2 and SJ McSorley1

Toll-like receptor 5 (TLR5) has been widely studied in an inflammatory context, but the effect of TLR5 on the adaptive response to bacterial flagellin has received considerably less attention. Here, we demonstrate that TLR5 expression by dendritic cells (DCs) allows a 1,000-fold enhancement of T-cell sensitivity to flagellin, and this enhancement did not require the expression of NLRC4 or Myd88. The effect of TLR5 on CD4 T-cell sensitivity was independent of the adjuvant effect of flagellin and TLR5 ligation did not alter the sensitivity of ovalbumin (OVA)-specific T cells to OVA. In the spleen, the exquisite T-cell sensitivity to flagellin was regulated by CD4+CD8a+DCs and was blocked by a monoclonal antibody to TLR5. In the mesenteric lymph nodes, flagellin-specific T-cell activation was regulated by a population of CD103–CD11b+DCs. Thus, TLR5 expression by mucosal and systemic DC subsets controls the sensitivity of the adaptive immune response to flagellated pathogens.

INTRODUCTION

Flagellin subunits form the major filament of the flagella and are produced in large quantities by flagellated bacteria.1 Different leukocyte populations express surface Toll-like receptor 5 (TLR5), which can recognize extracellular flagellin and initiate an inflammatory response.2 As with many TLRs, TLR5 signaling is dependent on the recruitment of adaptor protein Myd88, but does not utilize TRIF (TIR-domain-containing adaptor-inducing interferon-β).3 The conserved structure of bacterial flagellins ensures that TLR5 can detect a wide array of flagellated bacteria including Listeria, Salmonella, Legionella, and Pseudomonas.2,4 Bacterial flagellins can also be recognized by the inflammasome complex and induce inflammatory responses via NAIP5 and NLRC4.5–8 Given their proinflammatory properties, flagellins can function as effective adjuvants4,9 and are currently being tested in clinical trials.10,11 Unlike most TLR ligands, flagellins are also proteins and can be processed and presented by host major histocompatibility complex molecules and directly recognized by flagellin-specific T cells.12 Our laboratory and others have identified natural major histocompatibility complex class II epitopes of Salmonella flagellin,13–15 which has allowed detailed study of flagellin-specific T-cell responses in mice.12,16 Flagellin-specific CD4 T cells dominate the early immune response to intestinal Salmonella infection,14 and flagellins are also a major target antigen in murine and human inflammatory bowel disease.17 Immune reactivity to flagellins correlates with increasingly severe intestinal disease in patients with Crohn’s disease.18,19 Thus, flagellins are unusual bacterial proteins that can be simultaneously recognized by multiple innate and adaptive immune receptors.

Dendritic cells (DCs) are antigen-presenting cells that are uniquely able to integrate signals from TLRs and control the activation of naive T cells in secondary lymphoid tissues.20 It has been thought that murine splenic DCs lack TLR5 expression as they do not produce an inflammatory response to flagellin in vitro.21–23 Indeed, a comprehensive analysis of TLR5 expression found that TLR5-expressing DCs were restricted to the intestinal lamina propria (LP).24 However, a more recent study detected a TLR5-dependent adjuvant effect in draining lymph node DCs,25 demonstrating that TLR5 can be expressed by DCs outside the intestinal LP.

Recently, we reported a requirement for TLR5 expression for induction of adaptive immune responses to flagellin after
immunization or oral infection. Here, we have examined the role of TLR5 in DC antigen presentation of a natural flagellin epitope from Salmonella Typhimurium. We report that TLR5 is essential and NLRC4 dispensable for flagellin-specific CD4 T-cell expansion in vivo. Furthermore, expression of TLR5 allowed the host to mount a flagellin-specific immune response to very low amounts of antigen. This exquisite sensitivity to flagellin was also reproduced in vitro where TLR5 expression by DCs conferred a 1,000-fold increase in the ability to activate flagellin-specific CD4 T cells, an effect that was distinct from the adjuvant effect of flagellin and did not require NLRC4 or Myd88 expression. In addition, we identified CD4−CD8α− DCs in the spleen as a unique subset that can regulate enhanced activation of flagellin-specific CD4 T cells. Furthermore, a corresponding population of CD103−CD11b+ DCs isolated from the mesenteric lymph nodes (MLNs) was able to regulate T-cell sensitivity to bacterial flagellin in intestinal lymphoid tissues.

RESULTS

TLR5 expression is required for the clonal expansion of flagellin-specific T cells in vivo

Given the dominance of flagellin-specific T-cell responses in infectious and inflammatory disease, we examined how TLR5 or Myd88 expression affected the initial clonal expansion of ovalbumin (OVA)- or flagellin-specific T cells in vivo. C57BL/6 (wild-type) or TLR5-deficient mice were adoptively transferred with OVA-specific OT-II T cells, or flagellin-specific SM1 T cells, and immunized with a mixture of flagellin and OVA. OT-II T cells expanded similarly in wild-type, TLR5-, and Myd88-deficient mice (Figure 1), demonstrating that TLR5 or Myd88 are not essential for the initial clonal expansion of OVA-specific T cells. In marked contrast, SM1 T cells expanded in wild-type and Myd88-deficient mice, but failed to expand in TLR5-deficient mice (Figure 1). Although both SM1 and OT-II T cells expanded in Myd88-deficient mice, the level of expansion was slightly reduced compared with wild-type mice, most likely because of a reduction in the inflammatory response mediated by Myd88 (Figure 1). NLRC4 is an inflammasome component that allows intracellular recognition of flagellin, and has previously been implicated in the induction of flagellin-specific antibody responses. However, wild-type and NLRC4-deficient mice both developed robust SM1 clonal expansion 3 days after immunization of flagellin, although the level of expansion was slightly lower in NLRC4-deficient recipients (Figure 2). Together, these experiments demonstrate that TLR5 expression is required for the in vivo expansion of flagellin-specific CD4 T cells to flagellin immunization.

Figure 1 In vivo expansion of flagellin-specific T cells requires Toll-like receptor 5 (TLR5), but not Myd88. Wild-type, TLR5-deficient, and Myd88-deficient mice were adoptively transferred with 1 × 10^6 CD90.1 OT-II or SM1 T cell receptor (TCR) transgenic T cells and immunized with 100 μg ovalbumin (OVA) plus 1 μg flagellin. After 3 days, clonal expansion of OT-II and SM1 T cells was assessed in the spleen. (a) Fluorescence-activated cell sorting (FACS) plots show CD4 and CD90.1 staining of the gating on live cells. (b) Graphs show the mean percentage ± s.e.m. of OT-II and SM1 T cells. ***P < 0.0001, **P < 0.01, and *P < 0.05, as analyzed by two-way analysis of variance (ANOVA). NS, not significant.
immunization was absent in mice lacking TLR5 (Figure 3c,f). Indeed, SM1 T cells in TLR5-deficient mice were only able to respond to flagellin when doses of 1–100 µg were used (Figure 3c,f). This effect was distinct from the intrinsic adjuvant effect of flagellin as the expansion of OT-II T cells was unaffected by TLR5 deficiency, even when flagellin was used as an adjuvant, and T-cell expansion was also detected in Myd88-deficient mice (Figure 1). Thus, host expression of an innate receptor for flagellin (TLR5) allows for a 1,000-fold enhancement in the sensitivity of the adaptive immune response to this same antigen.

DC expression of TLR5 controls T-cell sensitivity to flagellin

Lymph node and splenic DCs are not thought to express TLR5 as these populations do not generate an inflammatory response to flagellins in vitro. We examined whether TLR5 expression by splenic DCs was responsible for the sensitivity of flagellin-specific T-cell activation. CD11c+ DCs from the spleens of wild-type and TLR5-deficient mice were enriched by magnetic selection (Supplementary Figure S1A online). CD11c+ DCs were incubated with OT-II or SM1 T cells in the presence or absence of OVA or flagellin, and T-cell activation was subsequently examined. At 16 h after incubation with 10–100 µg ml\(^{-1}\) of OVA, OT-II T cells displayed increased expression of CD69, whereas lower doses failed to activate OVA-specific T cells (Figure 4a, solid line). In a similar manner, SM1 T cells incubated with TLR5-deficient DCs were activated to express CD69 when a range of 1–100 µg ml\(^{-1}\) of flagellin was added to cultures (Figure 4b, dotted line). In marked contrast, DCs from wild-type mice were capable of activating SM1 T cells to express CD69 even when as little as 1 ng ml\(^{-1}\) of flagellin was used (Figure 4b, solid line). This difference in antigen-presenting capacity at low doses was absent when flagellin peptide was used as a stimulus rather than whole flagellin protein (Supplementary Figure S2 online), indicating that the enhanced sensitivity to flagellin in wild-type DCs is a consequence of TLR5 expression rather than intrinsic differences in the capacity to present antigen. This TLR5-dependent effect was also distinct from the adjuvant effect of flagellin in vitro, as the addition of flagellin in vitro did not improve the sensitivity of the OT-II responses to OVA (Figure 4c). Furthermore, activation of OT-II cells was largely unaffected by TLR5 deficiency, even when flagellin was added to cultures (Figure 4d).

Next, we examined the expression of multiple markers of CD4 T-cell activation following stimulation of flagellin-specific T cells with low-dose (1 ng ml\(^{-1}\)) flagellin. Wild-type DCs induced SM1 T cells to increase the expression of CD25 and CD69 at 16 h after adding flagellin, whereas TLR5-deficient DCs did not (Figure 5a). Similarly, at 48 h, wild-type DCs induced SM1 T cells to increase expression of CD44 and reduce expression of CD62L, whereas TLR5-deficient DCs did not (Figure 5a). Wild-type DCs also induced interleukin-2 (IL-2) production from naive SM1 T cells at much lower flagellin concentrations than TLR5-deficient DCs (Figure 5b).
In contrast, TLR5-deficient DCs were able to induce an equivalent response if flagellin peptide (427–441) was used to stimulate SM1 cells (Figure 5b). As Myd88 expression is required for all previously reported functions of TLR5, we examined the activation of SM1 T cells using Myd88-deficient DCs. Myd88-deficient DCs remained fully capable of activating

Figure 3  Toll-like receptor 5 (TLR5) enhances T-cell activation to low doses of flagellin. $1 \times 10^6$ carboxyfluorescein succinimidyl ester (CFSE)–labeled T cell receptor (TCR) transgenic T cells were adoptively transferred into wild-type and TLR5-deficient mice and the following day were immunized with different doses of ovalbumin (OVA; 1–100 μg) or flagellin (100 pg to 100 μg) plus 10 μg of lipopolysaccharide (LPS). After 3 days, clonal expansion of (a) OT-II or (b and c) SM1 T cells was examined in the spleen. Upper plots show staining of CD4 and CD90.1 to identify transgenic T cells and lower plots show CD11a and carboxyfluorescein succinimidyl ester (CFSE) staining after gating on OT-II and SM1 T cells. Each plot is a representative of three mice per group and two independent experiments. (d) Bar plots showing the percentage and total number of OT-II T cells in the spleen of OVA (1–100 μg) immunized animals. (e, f) Plots show the percentage and total number (± s.e.m.) of SM1 T cells in the spleen of (e) wild-type and (f) TLR5-deficient mice immunized with flagellin. Graphs combine the results of two independent experiments with three mice per group. Statistical significance was examined using unpaired t-test between the groups immunized with OVA (100 μg) or flagellin (1 μg) and transfer only. ***P < 0.0001, **P < 0.01, and *P < 0.05, as analyzed by unpaired t-test.
Figure 4  Toll-like receptor 5 (TLR5) expression by CD11c+ dendritic cells (DCs) controls the sensitivity of flagellin-specific T-cell activation. DCs isolated from C57BL/6 (wild-type) and TLR5-deficient mice were cultured with T cell receptor (TCR) transgenic (SM1 or OT-II) T cells and various concentrations of antigen (flagellin or ovalbumin (OVA)). (a) Graph shows increased expression of CD69 on gated (CD4+CD90.1+) OT-II T cells after 16 h of incubation with wild-type DCs and OVA (1 ng ml\(^{-1}\) to 100 \(\mu\)g ml\(^{-1}\)). (b) Graph shows increased expression of CD69 on (CD4+CD90.1+) SM1 T cells after 16 h of incubation in the presence of wild-type (solid line) or TLR5-deficient DCs (dotted line) with flagellin (1 ng ml\(^{-1}\) to 10 \(\mu\)g ml\(^{-1}\)) or flagellin peptide (6 \(\mu\)M). (c) DCs were cultured with TCR transgenic OT-II T cells and various concentrations of OVA (\(\mu\)g ml\(^{-1}\)), OVA plus flagellin, or OVA plus lipopolysaccharide (LPS). Graph shows increased expression of CD69 on gated (CD4+CD90.1+) OT-II T cells after 16 h of incubation with wild-type DCs. (d) DCs isolated from wild-type, TLR5-deficient, or Myd88-deficient mice were cultured with OT-II T cells and OVA (100 \(\mu\)g ml\(^{-1}\)) or OVA plus flagellin (1 ng ml\(^{-1}\)), or OVA plus LPS (1 ng ml\(^{-1}\)). Graph shows increased expression of CD69 on (CD4+CD90.1+) OT-II T cells after 16 h of incubation with wild-type, TLR5-deficient, or Myd88-deficient DCs.

Figure 5  Dendritic cell (DC) expression of Toll-like receptor 5 (TLR5), but not Myd88, is required to activate flagellin-specific T cells. DCs from the spleen of wild-type, TLR5-deficient, and Myd88-deficient mice were incubated with flagellin and SM1 T cells to examine T-cell activation. (a, b) 1 x 10^5 DCs were cultured with 1 x 10^5 SM1 T cells for 16 h (CD69 and CD25) or 48 h (CD44 and CD62L) in the presence of 10 ng ml\(^{-1}\) of flagellin (solid line) or medium alone (shaded area). (a) Plots show cell surface expression of CD69, CD25, CD44, or CD62L after gating on (CD4+CD90.1+) SM1 T cells. (b) Production of interleukin-2 (IL-2) in culture supernatants was assessed by enzyme-linked immunosorbent assay (ELISA) 48 h after incubation with different concentrations (Conc) of flagellin or medium alone. Graph shows mean IL-2 ± s.e.m. in tissue culture replicates after stimulation. (c) Prior treatment of DCs with a monoclonal anti-TLR5 antibody (mTLR5Ab; 10 \(\mu\)g ml\(^{-1}\)) for 60 min inhibited flagellin-specific activation of SM1 T cells. Plots show CD69 surface staining after gating on CD4+CD90.1+ SM1 T cells. All data are representative of three independent experiments.
SM1 T cells to modulate expression of activation markers and secrete IL-2 (Figure 5a,b). Thus, the sensitivity of flagellin-specific T cells is controlled by DC expression of TLR5, but does not require the expression of Myd88.

Next, we examined whether inhibition of flagellin binding to TLR5 could interfere with the ability of DCs to activate flagellin-specific T cells. Wild-type CD11c+ DCs isolated from the spleen were incubated with SM1 T cells, flagellin, and a blocking TLR5 monoclonal antibody. Inhibition of TLR5 binding eliminated SM1 T-cell activation (Figure 5c), whereas this same antibody had no effect on the T-cell response to processed flagellin peptide 427–441 (Figure 5c). Thus, physical interaction of flagellin with TLR5 on DCs is a prerequisite for TLR5 to enhance flagellin-specific T-cell responses.

**Splenic CD4−CD8α− myeloid DCs control T-cell responses to flagellin**

CD11c+ splenic DCs are a heterogeneous population and several different subsets have been defined based on the expression of CD8α, CD11b, and CD4.32,33 We examined whether these different splenic DC subsets were differentially able to activate flagellin-specific T cells in vitro. Initially, we isolated CD11c+CD8α+ and CD11c+CD8α− DCs and found that only myeloid (CD11c+CD8α−) DCs were capable of activating SM1 T cells to express CD69 and CD25 using flagellin as an antigen (Figure 6a). Examining this myeloid DC population further, we found that only CD11c+CD8α− DCs that lack CD4 expression were able to efficiently activate SM1 T cells in vitro, whereas CD4-expressing DCs did not (Figure 6b). Thus, the ability to sensitively activate flagellin-specific T cells is regulated by a minor population of splenic DCs that lack expression of both CD4 and CD8α.

**MLN CD103−CD11b+ DCs regulate T-cell responses to flagellin**

Flagellin-specific T-cell responses are often induced in the intestine and thus host immune sensitivity to flagellin is likely to be regulated by intestinal DC subsets.26,34,35 We therefore compared the ability of DCs from spleen, peripheral lymph nodes, and MLNs of wild-type and TLR5-deficient mice to activate SM1 T cells in vitro. CD11c+ DCs from each of these locations were able to activate flagellin-specific T cells in vitro to express CD69, and the expression of TLR5 was required in each case (Figure 7a–c). In contrast, wild-type and TLR5-deficient DCs were equivalently able to activate SM1 T cells in the presence of OVA (Supplementary Figure S3 online). In addition, flagellin-specific T-cell activation by wild-type DCs was blocked by the addition of an anti-TLR5 monoclonal antibody (Figure 7d). In contrast, CD11c+ DCs from the Peyer’s Patch or LP were poorly able to activate flagellin-specific T cells (Supplementary Figure S4 online), although the CD11c enrichment efficiency was somewhat lower for both these tissues.

Next, we enriched CD103+ and CD103− MLN DCs and examined whether these populations were differentially able to present flagellin (Supplementary Figure S1 online). Although CD103+ DCs were relatively poor at activating SM1 T cells, there was a small but significant increase in T-cell activation when CD103− DCs were used (Figure 8a). Similar to splenic DCs, when MLN DCs were enriched on expression of CD11b, there was a significant enhancement in the ability to present flagellin to SM1 T cells (Figure 8b). Furthermore, the ability of MLN CD11b+ DCs to present flagellin was blocked by the addition of a monoclonal antibody against TLR5 (Figure 8c). The difference in the ability of CD11b+ DCs to activate flagellin-specific T cells also correlated with increased TLR5 expression by this subset, as examined by reverse transcriptase–PCR analysis (Supplementary Figure S5 online). Together, these data suggest that CD103− and CD11b+ expression define a MLN DC subset with enhanced ability to initiate flagellin-specific T-cell responses to low doses of flagellin.

**DISCUSSION**

Immunologists have historically devoted a significant amount of attention to examining flagellin-specific immune responses due to the immunogenicity of this protein.36–39 For example, it was noted more than 40 years ago that immune response in rats can be induced with as little as 10 ng of flagellin.36,38 Our data
demonstrate that TLR5 expression largely accounts for the exquisite sensitivity of a mammalian host to respond to bacterial flagellin. This finding is important as it also provides a plausible explanation for the underlying dominance of flagellin-specific immune responses in infectious and inflammatory diseases of the intestine, perhaps especially so when overall antigen concentrations are very low, such as during the early stages of bacterial infection. However, it is also important to note that TLR5-deficient mice retain the ability to respond to concentrations of flagellin in the microgram range and this is similar to the threshold for OVA-specific responses. Thus, expression of TLR5 simply confers a unique sensitivity to low doses of flagellin in wild-type mice. Further studies will be required to determine whether the expression of TLR5 is required for directing flagellin-specific adaptive immunity during infection or inflammatory bowel disease.

Bacterial flagellin can also be recognized by NLRC4 (earlier known as ICE like protease activating factor (IPAF)) and NAIP5 in the cytosol.5–8 Recently, NLRC4 was reported to be essential for humoral responses to flagellin.31 However, our data demonstrate that NLRC4 plays at most a minor role in directing flagellin-specific T-cell activation, as the expansion and activation of SM1 T cells was similar in mice expressing or lacking NLRC4. Given the cytosolic location of inflammasome detection, it remains possible that NLRC4 plays a more important role in directing the CD8 T-cell responses; however, reagents to study flagellin-specific CD8 T cells are not yet available.
The spleen contains multiple DC subsets including CD4−CD8α+, CD4+CD8α−, and CD4−CD8α− populations. CD8α+ lymphoid DCs are prominent in the white pulp whereas CD8α− myeloid DCs localize to the marginal zone and bridging channels. Here, we show that myeloid CD4−DCs are also functionally specialized to activate flagellin-specific T cells at very low antigen concentrations. Similarly, the MLN contains multiple resident and migratory DC subsets and our data pinpoint CD11c+CD103−CD11b+ DCs as a subset that is specifically capable of activating flagellin-specific T-cell response at very low antigen concentrations. This subset is likely a blood-derived resident DC population that is found in all secondary lymphoid tissues, although further studies will be required to demonstrate this. The enhanced capacity to activate flagellin-specific T cells required the expression of TLR5 and was blocked by anti-TLR5. It seems likely therefore that TLR5 allows preferential delivery of flagellin to the major histocompatibility complex class II loading compartment, although this remains to be demonstrated in vitro or in vivo. It is important to note that the ability of these DC subsets to present flagellin to T cells is TLR5 dependent but independent of Myd88 and can be detected in splenic DCs that show low inflammatory responses to flagellin in vitro. Thus, this functionality is distinct from the inflammatory activity of flagellin mediated by TLR5 and could therefore require a co-receptor or unique signaling components. Indeed, a population of CD103+DCs in the LP have been noted to display inflammatory activity in response to flagellin, but we detected low responses from LP DCs in T-cell stimulation assays. These data suggest that different intestinal DC subsets may use TLR5 differentially to induce inflammatory responses in intestinal tissue or present antigen to CD4 T cells in secondary lymphoid tissues.

It is not yet clear whether the increased sensitivity to antigen conferred by TLR5 expression is typical of other TLRs. TLR11 also recognizes a protein ligand, profilin, and indeed, profilin-specific CD4 T cells are induced in a TLR11-dependent manner. It is possible that any protein ligand that is internalized via surface TLRs benefits from enhanced delivery to the class II processing pathway and therefore the mechanism of this enhanced delivery will be of interest to vaccine design. In conclusion, our study demonstrates the importance of TLR5 in...
DC antigen presentation by decreasing the threshold at which flagellin-specific T cells are activated and also suggests that TLR5 expression by distinct populations of splenic and intestinal dendritic cells are responsible for focusing host responses onto this antigen in infectious and inflammatory disease states. Given these findings, it is possible that this novel function of TLR5 can be utilized to improve the immunogenicity of enteric vaccines or prevent flagellin-specific responses in inflammatory disease.

METHODS
Mice and reagents. C57BL/6 and B6.SJL-PtprcaPep3b/BoyJ (CD45.1 congenic) mice (6–8 weeks old) were purchased from The Jackson Laboratory (Bar Harbor, ME) and NCI (Frederick, MD). TLR5-deficient and NLRC4-deficient mice43 were bred from stock originally provided by Dr A. Gewirtz (Georgia State University, Atlanta, GA). Myd88-deficient mice44 were provided by Dr S. Way (University of Minnesota Medical School, Minneapolis, MN). Rag-deficient, CD90.1 congenic, flagellin-specific SM1 T cell receptor transgenic mice have been described previously.26,27 Rag-deficient, OT-2 T cell receptor transgenic mice45 were backcrossed to a Rag-deficient CD90.1 congenic background in our laboratory. The flagellin epitope recognized by SM1 T cells (flagellin_{427-441}) has been reported, and this peptide was purchased from Invitrogen (Carlsbad, CA).

Adoptive transfer and immunization. Spleen, inguinal, brachial, cervical, and MLNs were harvested from SM1 or OT-II mice and red blood cells were lysed using ACK lysis buffer (Lonza, Walkersville, MD) before labeling with CFSE.46 The percentage of transgenic T cells was determined and 800,000–1 × 10⁶ cells transferred intravenously into mice. The following day, mice were injected intravenously with various doses of flagellin or OVA.

DC enrichment and in vitro stimulation. Spleens, peripheral lymph nodes, and MLNs were digested using collagenase D (Roche Diagnostics, Indianapolis, IN) and DCs enriched to greater than 85–95% purity using CD11c microbeads (Miltenyi Biotech, Auburn, CA). DC subsets were enriched by positive or negative selection using antibodies specific for CD11c, CD11b, CD103, or CD86 (Miltenyi Biotech). Further separation of splenic myeloid CD86+ DCs was accomplished using a CD4 isolation kit (Miltenyi Biotech). CD11b+ DCs were enriched using CD11b+ isolation kit (Miltenyi Biotech; Supplementary Figure S1 online). CD103+ DCs were isolated from negatively enriched CD11c+ DCs using CD103-specific antibody and streptavidin beads (Miltenyi Biotech). The unbound CD103− fraction was used to purify CD11b+ DCs. DC subsets (1 × 10⁶ cells per well) were incubated 1:1 with SM1 or OT-II T cells in the presence or absence of antigen. CD4 T cells were recovered at 16- and 48-h time points to examine activation by surface staining and cytokine production was detected in the supernatant. In some assays, DCs were also incubated with 10 μg ml⁻¹ neutralizing anti-TLR5 monoclonal antibody (Invivogen, San Diego, CA) for 60 min before addition of flagellin and SM1 T cells.

Flow cytometric analysis. DC subsets were characterized using antibodies specific for CD11c, CD11b, CD86, CD103, DEC205 (CD205), and CD4 (eBiosciences, San Diego, CA). T-cell activation was examined using antibodies specific for CD4, CD90.1, CD69, CD25, CD44, and CD62L (eBiosciences). Cells were analyzed using a BD Fortessa and data analyzed using FlowJo software (Treestar, Ashland, OR).

RNA isolation, complementary DNA synthesis, and reverse transcriptase–PCR. DCs were isolated from spleen and MLNs as described above. Total RNA was extracted using RNA Easy Mini Kit (Qiagen, Germantown, MD) and 100 ng RNA was reverse transcribed with taqman (Applied Biosystems, Grand Island, NY) following the manufacturer’s protocol. TLR5-specific primers were purchased from Invivogen and 5 μl of complementary DNA was used for the amplification from each sample. PCR conditions were exactly as suggested by Invivogen and PCR products were separated on a 2% agarose gel. Glyceraldehyde-3-phosphate dehydrogenase amplification was used as an internal control in each case.

Isolation of dendritic cells from LP and Peyer’s patch. The small intestine was removed from at least 5 to 6 mice and washed twice with phosphate-buffered saline to remove fecal contents before Peyer’s patches were excised. DCs were isolated from Peyer’s patches using CD11c microbeads, as described for other lymphoid tissues above. Cells were then passed through a 40-μm strainer and washed twice with MACS buffer before CD11c+ DCs were enriched using CD11c+ microbeads.

Statistical analysis. Statistical analysis of data was accomplished using InStat (GraphPad Software, La Jolla, CA). Data were compared using unpaired t-test between groups and were considered significantly different with a P-value of <0.05. Two-way analysis of variance analysis was also used for statistical analysis where appropriate.

ACKNOWLEDGEMENTS
We acknowledge helpful discussions with current and past members of the McSorley laboratory and the laboratory of Dr S. Way in completion of these experiments. This work was supported by grants from the National Institutes of Health AI073672 and AI055743.

DISCLOSURE
The authors declared no conflict of interest.

© 2014 Society for Mucosal Immunology

ARTICLES
